

# Human PLC $\zeta$ exhibits superior fertilization potency over mouse PLC $\zeta$ in triggering the Ca<sup>2+</sup> oscillations required for mammalian oocyte activation

Michail Nomikos<sup>1,\*</sup>, Maria Theodoridou<sup>1,2</sup>, Khalil Elgmati<sup>1</sup>,  
Dimitris Parthimos<sup>1</sup>, Brian L. Calver<sup>1</sup>, Luke Buntwal<sup>1</sup>,  
George Nounesis<sup>2</sup>, Karl Swann<sup>1</sup>, and F. Anthony Lai<sup>1,\*</sup>

<sup>1</sup>Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK <sup>2</sup>National Center for Scientific Research 'Demokritos', Aghia Paraskevi 15310, Greece

\*Correspondence address. E-mail: mixosn@yahoo.com (M.N.), lait@cf.ac.uk (F.A.L.)

Submitted on November 30, 2013; resubmitted on January 21, 2014; accepted on January 24, 2014

**ABSTRACT:** A sperm-specific phospholipase C-zeta (PLC $\zeta$ ) is believed to play an essential role in oocyte activation during mammalian fertilization. Sperm PLC $\zeta$  has been shown to trigger a prolonged series of repetitive Ca<sup>2+</sup> transients or oscillations in oocytes that precede activation. This remarkable intracellular Ca<sup>2+</sup> signalling phenomenon is a distinctive characteristic observed during *in vitro* fertilization by sperm. Previous studies have notably observed an apparent differential ability of PLC $\zeta$  from disparate mammalian species to trigger Ca<sup>2+</sup> oscillations in mouse oocytes. However, the molecular basis and confirmation of the apparent PLC $\zeta$  species difference in activity remains to be provided. In the present study, we provide direct evidence for the superior effectiveness of human PLC $\zeta$  relative to mouse PLC $\zeta$  in generating Ca<sup>2+</sup> oscillations in mouse oocytes. In addition, we have designed and constructed a series of human/mouse PLC $\zeta$  chimeras to enable study of the potential role of discrete PLC $\zeta$  domains in conferring the enhanced Ca<sup>2+</sup> signalling potency of human PLC $\zeta$ . Functional analysis of these human/mouse PLC $\zeta$  domain chimeras suggests a novel role of the EF-hand domain in the species-specific differences in PLC $\zeta$  activity. Our empirical observations are compatible with a basic mathematical model for the Ca<sup>2+</sup> dependence of generating cytoplasmic Ca<sup>2+</sup> oscillations in mammalian oocytes by sperm PLC $\zeta$ .

**Key words:** phospholipase C / PLCzeta / sperm / fertilization / oocyte activation / male infertility

## Introduction

At fertilization, the first event following the fusion of the sperm and oocyte membranes is a series of transient rises in the intracellular-free Ca<sup>2+</sup> concentration, termed Ca<sup>2+</sup> oscillations. In human and other oocytes, these Ca<sup>2+</sup> oscillations persist for several hours after gamete fusion (Miyazaki *et al.*, 1993). Prolonged Ca<sup>2+</sup> oscillations have also been observed after intra-cytoplasmic sperm injection (ICSI) in both human and mouse oocytes (Tesarik *et al.*, 1994; Nakano *et al.*, 1997). In all species studied, such Ca<sup>2+</sup> oscillations are both necessary and sufficient for the completion of all the events of oocyte activation and early embryonic development (Nomikos *et al.*, 2012). Ca<sup>2+</sup> oscillations in mammalian oocytes occur as a result of inositol trisphosphate (IP<sub>3</sub>)-mediated Ca<sup>2+</sup> release from internal stores such as the endoplasmic

reticulum (ER) (Miyazaki *et al.*, 1992), with the amplitude, duration and frequency of Ca<sup>2+</sup> oscillations being largely species specific (Swann *et al.*, 2006; Nomikos *et al.*, 2012). However, the sperm factor causing the Ca<sup>2+</sup> oscillations is not species specific because the injection of human sperm into mouse oocytes can cause Ca<sup>2+</sup> oscillations as well as oocyte activation (Vanden Meerschaut *et al.*, 2013). Since it is the Ca<sup>2+</sup> oscillations that trigger embryo development, the outcome of such heterologous ICSI has been suggested as a method for evaluating cases of oocyte activation failure after human ICSI (Vanden Meerschaut *et al.*, 2013).

Over the past decade, mounting experimental and clinical evidence suggests that the factor responsible for the initiation of Ca<sup>2+</sup> oscillations during mammalian fertilization is a testis-specific isoform of phospholipase C (PLC), PLC-zeta (PLC $\zeta$ ) (Cox *et al.*, 2002; Saunders *et al.*, 2002;

Kouchi et al., 2004; Yoon et al., 2008; Heytens et al., 2009; Kashir et al., 2010). Sperm-delivered PLC $\zeta$  is believed to catalyse phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) hydrolysis within the fertilized oocyte, stimulating the inositol 1,4,5-trisphosphate (InsP<sub>3</sub>) signalling pathway leading to Ca<sup>2+</sup> oscillations (Saunders et al., 2002; Nomikos et al., 2012). The significance of PLC $\zeta$  in human fertilization has been emphasized by recent clinical studies that have linked abnormal expression, localization and defects in PLC $\zeta$  protein structure with cases of oocyte activation deficiency and subsequently with male infertility (Yoon et al., 2008; Heytens et al., 2009; Nomikos et al., 2011a; Kashir et al., 2012). Human sperm lacking PLC $\zeta$  have also been shown to be deficient in causing Ca<sup>2+</sup> oscillations in heterologous ICSI with mouse oocytes (Yoon et al., 2008). The clinical potential of PLC $\zeta$  was also recently highlighted by the use of recombinant human PLC $\zeta$  protein (Nomikos et al., 2013). It was demonstrated that in a prototype of male factor infertility, microinjection of recombinant human PLC $\zeta$  could phenotypically rescue failed activation of mouse oocytes expressing dysfunctional PLC $\zeta$ , leading to efficient blastocyst formation (Nomikos et al., 2013).

Similar to other PLC isoforms, PLC $\zeta$  demonstrates a typical PLC domain structure with four tandem EF-hand domains at the N-terminus, followed by the characteristic X and Y catalytic domains, which form the active site in all PLC isoforms, and a single C2 domain at the C-terminus (Saunders et al., 2002). Each of the individual PLC $\zeta$  domains appears to have an essential role in the distinct biochemical characteristics and the unique mode of regulation of this gamete-specific PLC isozyme (Nomikos et al., 2005, 2007, 2011b). A major difference of the sperm PLC $\zeta$  to somatic cell PLC isoforms is the absence of a pleckstrin homology domain (Saunders et al., 2002). This makes PLC $\zeta$  the smallest known mammalian PLC with a molecular mass of ~70 kDa in humans and ~74 kDa in mice (Cox et al., 2002; Saunders et al., 2002). Notably, there appear to be substantial differences in the relative potency of PLC $\zeta$  from different species (Swann et al., 2006; Saunders et al., 2007; Cooney et al., 2010; Bedford-Guaus et al., 2011). Previous reports have suggested that it takes nearly >10 times less human PLC $\zeta$  cRNA than mouse PLC $\zeta$  cRNA to trigger Ca<sup>2+</sup> oscillations in mouse oocytes (Cox et al., 2002). These species differences in PLC $\zeta$  effectiveness may explain why even 'dead' human sperm can still be shown to cause some Ca<sup>2+</sup> oscillations in mouse oocytes (Yazawa et al., 2009). However, the expression levels have not been carefully measured in the same set of experiments with both mouse and human PLC $\zeta$  and so the precise difference in potency between these species is not clear. There have also been no parallel studies of the comparative *in vitro* enzymatic characteristics of recombinant human and mouse PLC $\zeta$ . In addition, the domain(s) of human PLC $\zeta$  that might contribute significantly to the greater potency of human PLC $\zeta$  are currently unknown.

In the present study, we provide a quantitative and qualitative comparison of the relative potencies of human and mouse PLC $\zeta$  by using luciferase-tagged fusion proteins, and by using this approach we have determined the specific degree to which human PLC $\zeta$  is more effective than mouse PLC $\zeta$  in generating Ca<sup>2+</sup> oscillations in mouse oocytes. Recombinant human PLC $\zeta$  also displayed a higher *in vitro* PIP<sub>2</sub> hydrolysis activity than mouse PLC $\zeta$ . By preparing human/mouse PLC $\zeta$  domain 'swaps', this has enabled chimeric protein analysis to demonstrate that replacement of the human PLC $\zeta$  C2 domain with the corresponding mouse C2 domain did not alter the *in vitro* and *in vivo* enzymatic properties of human PLC $\zeta$ . However, exchanging the human for mouse EF-hand

domain reduced the Ca<sup>2+</sup> oscillation-inducing activity by altering the Ca<sup>2+</sup> sensitivity and affinity of human PLC $\zeta$  for PIP<sub>2</sub>. Finally, our data suggest that replacement of the human PLC $\zeta$  XY-linker with the corresponding region of mouse PLC $\zeta$  dramatically affects the stability of the protein, suggesting a significant role of the XY-linker region in species-specific differences in PLC $\zeta$  Ca<sup>2+</sup> oscillation-inducing activity.

## Materials and Methods

### Cloning of PLC $\zeta$ human–mouse chimeric constructs

The hPLC $\zeta$ /mEF-luc and hPLC $\zeta$ /mC2-luc constructs were cloned into pCR3 vector by using a three-step cloning strategy. For hPLC $\zeta$ /mEF-luc, the EF hands of mouse PLC $\zeta$  (1–149aa) were amplified from the original cDNA clone (GenBank™ accession number AF435950) by PCR using *Phusion* polymerase (Finnzymes) and the appropriate primers to incorporate a 5'-KpnI site and a 3'-EcoRI site and cloned into the pCR3 vector. Human PLC $\zeta$  (143–608aa) was then amplified from the original cDNA clone (GenBank™ accession number AF532185) with the appropriate primers to incorporate a 5'-EcoRI site and a 3'-NotI site in which the stop codon had been removed and cloned into the pCR3-mEF<sup>1–149</sup> plasmid. Finally, the firefly (*Photinus pyralis*) luciferase open reading frame was amplified from pGL2 (Promega) with primers incorporating NotI sites and the product was cloned into the NotI site of the pCR3-mEF<sup>1–149</sup>-PLC $\zeta$ <sup>143–608</sup> plasmid. For hPLC $\zeta$ /mC2-luc, human PLC $\zeta$  (1–481aa) was amplified from the original cDNA clone by PCR using *Phusion* polymerase (Finnzymes) and with the appropriate primers to incorporate a 5'-EcoRI site and a 3'-EcoRV site and cloned into the pCR3 vector. Mouse PLC $\zeta$  C2 domain (520–647aa) was then amplified from the original cDNA clone with the appropriate primers to incorporate a 5'-EcoRV site and a 3'-NotI site in which the stop codon had been removed and cloned into the pCR3-hPLC $\zeta$ <sup>1–481</sup> plasmid. Finally, luciferase open reading frame was amplified from pGL2 (Promega) with primers incorporating NotI sites and the product was cloned into the NotI site of the pCR3-hPLC $\zeta$ <sup>1–481</sup>-mC2<sup>520–647</sup> plasmid. Human PLC $\zeta$ /mXYlink-luc construct was cloned into pCR3 vector by using a four-step cloning strategy. First, hPLC $\zeta$ (1–299aa) was amplified by PCR and with the appropriate primers to incorporate a 5'-KpnI site and a 3'-EcoRI site and cloned into the pCR3 vector. The XY-linker of mouse PLC $\zeta$  (308–385aa) was then amplified from the original cDNA clone with the appropriate primers to incorporate a 5'-EcoRI site and a 3'-EcoRV site and cloned into the pCR3-hPLC $\zeta$ <sup>1–299</sup> plasmid. Then, hPLC $\zeta$ (349–608aa) was amplified with the appropriate primers to incorporate a 5'-EcoRV site and a 3'-NotI site and cloned into the pCR3-hPLC $\zeta$ <sup>1–299</sup>-mPLC $\zeta$ <sup>308–385</sup> plasmid. Finally, as described for the first two chimeric constructs, luciferase open reading frame was amplified from pGL2 with primers incorporating NotI sites and the product was cloned into the NotI site of the pCR3-hPLC $\zeta$ <sup>1–299</sup>-mPLC $\zeta$ <sup>308–385</sup>-hPLC $\zeta$ <sup>349–608</sup> plasmid.

All the above chimeric constructs without the C'-terminus luciferase were amplified from the pCR3 vector with the appropriate primers to incorporate a 5'-Sall site and a 3'-NotI site and cloned into the pETMM60 vector to enable bacterial protein expression. Each of the above expression vector constructs was confirmed by dideoxynucleotide sequencing (Prism Big Dye kit; ABI Prism® 3100 Genetic Analyzer, Applied Biosystems, Warrington, UK).

### cRNA synthesis

Following linearization of wild-type and chimeric PLC $\zeta$  plasmids, cRNA was synthesized using the mMessage Machine T7 kit (Ambion) and then was polyadenylated using the poly(A) tailing kit (Ambion), as per the manufacturer's instructions.

## Preparation and handling of gametes

Female mice were superovulated and oocytes were collected 13.5–14.5 h after injection of human chorionic gonadotrophin and maintained in droplets of M2 media (Sigma) or H-synthetic oviductal medium enriched with potassium (KSOM) under mineral oil at 37°C. Microinjection of the oocytes was carried out 14.5–15.5 h after the hormone injection. Experimental recordings of Ca<sup>2+</sup> or luciferase expression were carried out with mouse oocytes in HEPES-buffered media (H-KSOM) as described previously (Nomikos *et al.*, 2005, 2011b, c, 2013). All compounds were from Sigma unless stated otherwise. All procedures using animals were performed in accordance with the UK Home Office Animals Procedures Act and were approved by the Cardiff University Animals Ethics Committee.

## Microinjection and measurement of intracellular Ca<sup>2+</sup> and luciferase expression

Mouse oocytes were washed in M2 and microinjected with cRNA diluted in injection buffer (120 mM KCl, 20 mM HEPES, pH 7.4). The volume injected was estimated from the diameter of cytoplasmic displacement caused by the bolus injection. All injections were 3–5% of the oocyte volume. Oocytes were microinjected with the appropriate cRNA, mixed with an equal volume of 1 mM Oregon Green BAPTA dextran (Molecular Probes) in the injection buffer. Oocytes were then maintained in H-KSOM containing 100  $\mu$ M luciferin and imaged on a Nikon TE2000 or Zeiss Axiovert 100 microscope equipped with a cooled intensified charge-coupled device camera (Photek Ltd., UK). The luminescence (for luciferase expression) and fluorescence (for Ca<sup>2+</sup> measurements) from eggs were collected by switching back and forth between two modes on a 10 s cycle (Swann *et al.*, 2009; Nomikos *et al.*, 2011a). These two signals are then displayed as two separate signals over the same time period. The fluorescent light used to measure Ca<sup>2+</sup> is shown in relative units because we are essentially interested in the frequency or number of Ca<sup>2+</sup> spikes. The luminescence from oocytes was converted into an amount of luciferase using a standard curve that was generated by placing oocytes in a luminometer that had been previously calibrated by microinjection with known amounts of luciferase protein (Sigma) (Nomikos *et al.*, 2005, 2011b, c, 2013; Swann *et al.*, 2009). All live imaging experiments on oocytes were made during a 3-month period.

## Protein expression and purification

For NusA-6xHis-fusion protein expression, *Escherichia coli* [Rosetta (DE3); Novagen], transformed with the appropriate pETMM60 plasmid, was cultured at 37°C until A<sub>600</sub> reached 0.6, and protein expression was induced for 18 h, 16°C with 0.1 mM isopropyl  $\beta$ -D-1-thiogalactopyranoside (Promega). Cells were harvested (6000 g for 10 min), resuspended in phosphate-buffered saline (PBS) containing protease inhibitor mixture (EDTA-free; Roche) and sonicated 4  $\times$  15 s on ice. Soluble NusA-6xHis-fusion protein was purified on Ni-NTA resin following standard procedures (Qiagen) and eluted with 275 mM imidazole. Eluted proteins were dialysed overnight (10 000 MWCO; Pierce) at 4°C against 4 l of PBS and concentrated with centrifugal concentrators (Sartorius; 10 000 MWCO).

## Assay of PLC activity

PIP<sub>2</sub> hydrolytic activity of recombinant PLC proteins was assayed as described previously. The final concentration of PIP<sub>2</sub> in the reaction mixture was 220  $\mu$ M, containing 0.05  $\mu$ Ci of [<sup>3</sup>H]PIP<sub>2</sub>. The assay conditions were optimized for linearity, requiring a 10-min incubation of 20 pmol of PLC $\zeta$  protein sample at 25°C. In assays to determine dependence on PIP<sub>2</sub> concentration, 0.05  $\mu$ Ci of [<sup>3</sup>H]PIP<sub>2</sub> was mixed with cold PIP<sub>2</sub> to give the appropriate final concentration. In assays examining the Ca<sup>2+</sup> sensitivity, Ca<sup>2+</sup> buffers were prepared by EGTA/CaCl<sub>2</sub> admixture, as described previously (Nomikos *et al.*, 2005, 2011b; 2013).

## SDS-PAGE and western blotting

Recombinant proteins were separated by SDS-PAGE as described previously (Nomikos *et al.*, 2011b; 2013). Separated proteins were transferred onto polyvinylidene difluoride membrane (Immobilon-P; Millipore) using a semi-dry transfer system (Trans-Blot SD; Bio-Rad) in buffer (48 mM Tris, 39 mM glycine, 0.0375% SDS) at 22 V for 4 h. The membrane incubated overnight at 4°C in Tris-buffered saline, 0.1% Tween 20 (TBS-T) containing 5% non-fat milk powder and probed with Penta-His monoclonal antibody (1 : 5000 dilution). Detection of horseradish peroxidase-coupled secondary antibody was achieved using enhanced chemiluminescence detection (ECL; Amersham Biosciences).

## Mathematical modelling


To investigate a range of mechanisms that are potentially responsible for the variable action of human and mouse isoforms of PLC $\zeta$ , we have employed a mathematical modelling approach. The model (outlined in detail in the Appendix) includes minor modifications from the mathematical description previously published in (Theodoridou *et al.*, 2013) and accounts for cytosolic Ca<sup>2+</sup> concentrations, Ca<sup>2+</sup> concentrations in the ER and cytosolic levels of IP<sub>3</sub>. In addition, the role of PIP<sub>2</sub> hydrolysis by PLC $\zeta$  has been investigated by using PIP<sub>2</sub> concentrations both as an implicit and as an independent variable. The model has been developed to reproduce the characteristic sequence of sperm-induced Ca<sup>2+</sup> spikes that are associated with the early stages of oocyte fertilization. The mathematical description of oocyte Ca<sup>2+</sup> dynamics has been derived from previously developed models of intracellular Ca<sup>2+</sup> dynamics in somatic cells that are based on Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release and IP<sub>3</sub>-induced Ca<sup>2+</sup> release (ICR) from the ER, that have been validated through extensive pharmacological probing (Parthimos *et al.*, 2007; 2009). Numerical simulations were run in parallel on code composed in C++ and MATLAB software (Mathworks).

## Results

### Ca<sup>2+</sup> oscillations induced by human, mouse and human/mouse PLC $\zeta$ chimeras


To compare the relative potencies of human and mouse PLC $\zeta$  in generating Ca<sup>2+</sup> oscillations within the same batch of mature mouse oocytes and to enable direct and quantitative comparison of relative protein expression within the mouse oocytes, we used luciferase-fusion protein constructs of human and mouse PLC $\zeta$  that we have characterized in previous studies (Nomikos *et al.*, 2005, 2011b, c; 2013). In addition, in order to investigate the potential importance of human PLC $\zeta$  domains in any species-specific differences in activity observed for human versus mouse PLC $\zeta$ , three chimeric plasmids were constructed. To generate these chimeric plasmids, human PLC $\zeta$  served as the template and then discrete protein domains were individually replaced by the corresponding domain of mouse PLC $\zeta$  (Fig. 1). The three chimeric constructs comprised human PLC $\zeta$  containing either the EF-hand domain (hPLC $\zeta$ /mEF), the C2 domain (hPLC $\zeta$ /mC2) or the XY-linker region (hPLC $\zeta$ /mXYlink) from mouse PLC $\zeta$  (Fig. 1). Similar to the wild-type human and mouse PLC $\zeta$  constructs, each of the human/mouse PLC $\zeta$  chimeras was tagged at the C-terminus with luciferase to enable us to verify and quantify their relative expression upon microinjection of the corresponding cRNA into mouse oocytes. As we have previously described, the advantage of this strategy is that enables real-time monitoring of the relative protein expression by luminescence quantification of the recombinant luciferase protein (Swann *et al.*, 2009).

Figure 2 and Table 1 summarize the results of the wild-type human, mouse and chimeric PLC $\zeta$ -luciferase cRNA microinjection experiments.



Consistent with our previous studies, prominent  $\text{Ca}^{2+}$  oscillations ( $\sim 20$  spikes/2 h) were observed in the mouse PLC $\zeta$  cRNA-injected oocytes, with the first  $\text{Ca}^{2+}$  spike occurring after  $\sim 30$  min at a luminescence reading of 0.85 counts per second (cps) and a peak luminescence level of  $\sim 19$  cps at the end of the experiment. Microinjection of cRNA encoding human PLC $\zeta$  also triggered  $\text{Ca}^{2+}$  oscillations in the same set of mouse oocytes, but exhibiting a higher frequency to mouse PLC $\zeta$  ( $\sim 46.2$  spikes/2 h), although we had microinjected 20-fold less cRNA for human compared with mouse PLC $\zeta$ , resulting in a peak luminescence level of 7.6 cps for human PLC $\zeta$ . Interestingly, the first  $\text{Ca}^{2+}$  spike with human PLC $\zeta$  was detected at a mean luminescence of 0.17 cps,  $\sim 20$  min post-cRNA microinjection. These data show that human PLC $\zeta$  is more effective than mouse PLC $\zeta$  in triggering  $\text{Ca}^{2+}$  oscillations. Judging by the number of  $\text{Ca}^{2+}$  spikes (in 2 h) per unit of expression (in cps), then human PLC $\zeta$  (6.08) can be seen to be about six times more effective at causing  $\text{Ca}^{2+}$  oscillations than mouse PLC $\zeta$  (1.05). If we use the threshold for initiating  $\text{Ca}^{2+}$  oscillations then human PLC $\zeta$  (0.17 cps) is five times more effective than mouse PLC $\zeta$  (0.85 cps).

Microinjection of cRNA corresponding to hPLC $\zeta$ /mC2 chimera induced  $\text{Ca}^{2+}$  oscillations in oocytes with a similar frequency to wild-type human PLC $\zeta$  ( $\sim 49.1$  spikes/2 h versus 46.2 spikes/2 h), with the first  $\text{Ca}^{2+}$  spike occurring (similar to human PLC $\zeta$ ) after  $\sim 20$  min at a luminescence reading of 0.32 cps (Fig. 2, Table I). In contrast, microinjection of oocytes with cRNA corresponding to hPLC $\zeta$ /mEF chimera showed a reduced frequency of  $\text{Ca}^{2+}$  oscillations compared with wild-type human PLC $\zeta$  ( $\sim 32.4$  spikes/2 h versus 46.2 spikes/2 h), even though this chimeric protein was expressed at  $\sim 7$ -fold higher levels compared with wild-type human PLC $\zeta$ , showing a peak luminescence level of 51.5 cps (versus 7.6 cps). The first  $\text{Ca}^{2+}$  spike was detected  $\sim 25$  min post-injection at a luminescence reading of 1.42 cps, which is  $\sim 8$ -fold higher than for wild type. Interestingly, microinjection of cRNA corresponding to the hPLC $\zeta$ /mXYlink chimera showed very low protein



**Figure 2** Expression of human PLC $\zeta$ , mouse PLC $\zeta$  and human/mouse PLC $\zeta$  chimeras in unfertilized mouse oocytes. Fluorescence and luminescence recordings reporting the  $\text{Ca}^{2+}$  changes (black traces;  $\text{Ca}^{2+}$ ) and luciferase expression [(red traces; Lum, in counts per second (cps)], respectively, in unfertilized mouse oocytes following microinjection of cRNA encoding luciferase-tagged hPLC $\zeta$ , mPLC $\zeta$ , hPLC $\zeta$ /mEF, hPLC $\zeta$ /mC2 and hPLC $\zeta$ /mXYlink.

expression (peak luminescence of 0.77 cps) even when 100-fold more cRNA was injected compared with human PLC $\zeta$ . The hPLC $\zeta$ /mXYlink chimera induced very low frequency  $\text{Ca}^{2+}$  oscillations ( $\sim 2.5$  spikes/2 h) with the first  $\text{Ca}^{2+}$  spike occurring after  $\sim 130$  min at a luminescence reading of 0.60 cps.

**Table I** Expression of microinjected cRNA encoding luciferase-tagged human PLC $\zeta$ , mouse PLC $\zeta$  and human/mouse PLC $\zeta$  chimeras.

PLC protein	Ca <sup>2+</sup> oscillations in the first 2 h (spikes/2 h)	Peak lumin. (cps)	Time to first spike (min)	Lumin. at first spike (cps)	No. of mouse eggs
hPLC $\zeta$	46.2 ± 5.40	7.60 ± 1.28	~20	0.17 ± 0.03	11
mPLC $\zeta$	20.2 ± 1.46	18.8 ± 0.73	~30	0.85 ± 0.09	10
hPLC $\zeta$ /mEF	32.4 ± 1.90	51.50 ± 3.16	~25	1.42 ± 0.18	12
hPLC $\zeta$ /mC2	49.1 ± 2.89	14.6 ± 0.89	~20	0.32 ± 0.03	17
hPLC $\zeta$ /mXYlink.	2.5 ± 0.40	0.77 ± 0.03	~130	0.60 ± 0.03	28

Ca<sup>2+</sup> oscillation-inducing activity (Ca<sup>2+</sup> spike number in 2 h) and luciferase luminescence levels (peak luminescence and luminescence at first spike) are summarized for mouse oocytes microinjected with each of the PLC-luciferase constructs (see Fig. 1A). Values are mean ± SEM.

These data indicate that the wild-type human PLC $\zeta$  is five to six times more effective in inducing Ca<sup>2+</sup> oscillations compared with wild-type mouse PLC $\zeta$ , even in a heterologous set of oocytes. In contrast to this intrinsic difference in wild-type activity, we found that substitution of the human PLC $\zeta$  C2 domain with the corresponding structure from mouse PLC $\zeta$  did not alter the Ca<sup>2+</sup> oscillation-inducing activity. However, substitution of the human PLC $\zeta$  EF-hand domain for that from mouse PLC $\zeta$  significantly reduced the Ca<sup>2+</sup> oscillation-inducing activity. Finally, replacement of the human PLC $\zeta$  XY-linker with the corresponding region of mouse PLC $\zeta$  appears to dramatically affect the expression levels of the chimeric PLC $\zeta$  in mouse oocytes.

### Enzymatic characterization of human, mouse and human/mouse PLC $\zeta$ chimeras

Wild-type mouse PLC $\zeta$  and all three human/mouse chimeric PLC $\zeta$  constructs were subcloned into the pETMM60 vector and purified as NusA-6xHis-tagged fusion proteins. We have recently demonstrated that NusA is an effective fusion protein partner for human PLC $\zeta$ , significantly increasing the expression of soluble PLC $\zeta$  protein in *E. coli*, as well as enhancing the stability of the purified protein over time (Nomikos *et al.*, 2013). Expression of active recombinant human PLC $\zeta$  protein has also been reported by other groups (Kashir *et al.*, 2011; Yoon *et al.*, 2012). Following expression of NusA-PLC $\zeta$  fusion proteins in *E. coli* and purification by Ni-NTA affinity chromatography, the recombinant proteins were characterized. Figure 3 shows NusA-tagged wild-type human and mouse PLC $\zeta$ , as well as the three PLC $\zeta$  chimeras analysed by SDS-PAGE (upper panel) and immunoblot detection with penta-His mouse monoclonal antibody (lower panel). The major protein band with mobility corresponding to the predicted molecular mass for each construct was observed for all except the hPLC $\zeta$ /mXYlink chimera. These major bands were also confirmed by the penta-His antibody after immunoblot analysis (Fig. 3; lower panel). Interestingly, in the case of hPLC $\zeta$ /mXYlink chimera the major band appeared to be ~103 kDa instead of the expected ~133 kDa, suggesting protein degradation due to the mouse XY-linker region resulting from instability of the purified recombinant protein. This protein instability might explain the very low expression levels of this chimera in mouse oocytes.


The specific PIP<sub>2</sub> hydrolytic enzyme activity for each recombinant protein was determined by the standard [<sup>3</sup>H]PIP<sub>2</sub> hydrolysis assay. The

histogram of Fig. 4A and Table II summarizes the enzyme specific activity values obtained for each recombinant protein. The enzymatic activities of wild-type human and mouse PLC $\zeta$  are in agreement with our previous observations revealing that human PLC $\zeta$  exhibits a ~76% higher specific activity than mouse PLC $\zeta$  (978 ± 34 versus 556 ± 29 nmol/min/mg). The specific activity for hPLC $\zeta$ /mC2 chimera was similar to the specific activity of wild-type human PLC $\zeta$  (970 ± 42 versus 978 ± 34 nmol/min/mg), in contrast with hPLC $\zeta$ /mEF chimera that showed a reduced enzymatic activity (~20%) compared with human PLC $\zeta$  (782 ± 33 versus 978 ± 34 nmol/min/mg). In accord with the poor activity observed in oocytes, the hPLC $\zeta$ /mXYlink chimera did not exhibit *in vitro* enzymatic activity.

To investigate the effect of single domain replacement on the Ca<sup>2+</sup> sensitivity of PLC $\zeta$  enzyme activity, we assessed the ability of wild-type human, mouse and chimeric PLC $\zeta$  proteins to hydrolyse [<sup>3</sup>H]PIP<sub>2</sub> at different Ca<sup>2+</sup> concentrations ranging from 0.1 nM to 0.1 mM. The resulting EC<sub>50</sub> value for human PLC $\zeta$  (49 nM), mouse PLC $\zeta$  (43 nM) and hPLC $\zeta$ /mC2 (40 nM) were near identical (Fig. 4B, Table II). However, replacement of EF hands from human PLC $\zeta$  with those from mouse PLC $\zeta$  increased the EC<sub>50</sub> value of human PLC $\zeta$  by ~3-fold (148 nM). To compare the enzyme kinetics of wild-type human and mouse PLC $\zeta$  and the three PLC $\zeta$  chimeras, the Michaelis-Menten constant, K<sub>m</sub> was calculated for each construct (Table II). The K<sub>m</sub> values obtained for human PLC $\zeta$  (75 μM), mouse PLC $\zeta$  (99 μM) and the hPLC $\zeta$ /mC2 (89 μM) chimera were quite similar. In contrast, the K<sub>m</sub> for hPLC $\zeta$ /mEF chimera was ~6.3-fold (475 μM) higher than that of human PLC $\zeta$ , suggesting that replacement of the EF hand of human from that of mouse PLC $\zeta$  reduces the *in vitro* affinity for PIP<sub>2</sub>.

### Modelling of Ca<sup>2+</sup> oscillations induced by human and mouse PLC $\zeta$

The above data show that human PLC $\zeta$  is more active than mouse PLC $\zeta$  both *in vitro* and in intact oocytes. However, the differences in ability to cause Ca<sup>2+</sup> oscillations is more dramatic (5- to 6-fold) than that for maximum enzymatic activity (~2-fold). We employed a mathematical model of IP<sub>3</sub>-induced Ca<sup>2+</sup> oscillations to understand this apparent discrepancy. The distinguishing properties that we examined were the Ca<sup>2+</sup>-dependence EC<sub>50</sub> values, PIP<sub>2</sub> hydrolytic activities and K<sub>m</sub>s for PIP<sub>2</sub> for human and mouse PLC $\zeta$  (Table II). However, the main difference is that the intrinsic hydrolytic activity for human PLC $\zeta$  is almost twice that




**Figure 3** Expression and purification of recombinant NusA-6xHis-tagged human, mouse and human/mouse PLC $\zeta$  chimeric proteins. Affinity-purified, NusA-6His-PLC fusion proteins (1  $\mu$ g) were analysed by 7.5% SDS-PAGE followed by either Coomassie Brilliant Blue staining (upper panel) or immunoblot analysis using the Penta-His monoclonal antibody (1:5000 dilution) (lower panel).

of mouse PLC $\zeta$ . Experimental estimates summarized in Tables I and II have been employed as parametric values in Equations (1–3) (Appendix), while a full list of coefficient/parameter values is provided in Table III. Numerical simulations generated under these assumptions produce sustained  $\text{Ca}^{2+}$  oscillations associated with the specific action of human and mouse PLC $\zeta$  (Fig. 5A). In each of the two cases, we mimicked the effect of increasing expression of PLC $\zeta$  with time as a sigmoidal, in agreement with luminescence traces presented in Fig. 1B. Simulated traces presented in Fig. 5A closely match the  $\text{Ca}^{2+}$  oscillations recorded in mouse oocytes (Fig. 2) both in terms of oscillatory  $\text{Ca}^{2+}$  frequency (Table I) and in terms of the protein expression level associated with onset of oscillations (Table I). Importantly, the earlier onset of oscillatory activity for human PLC $\zeta$  followed by an earlier frequency saturation underlines the potential for even higher activity of the human versus mouse PLC $\zeta$  (possibly up to a 6-fold potency ratio). These simulations demonstrate that the different enzymatic properties we observe for the recombinant human versus mouse PLC $\zeta$  can explain the difference in the frequency of  $\text{Ca}^{2+}$  oscillations we see in mouse oocytes.

## Discussion

A growing body of evidence supports the assertion that sperm-specific PLC $\zeta$  is the molecule that stimulates cytoplasmic  $\text{Ca}^{2+}$  oscillations at



**Figure 4** *In vitro* enzymatic properties of human/mouse PLC $\zeta$  chimeras. (A) [ $^3\text{H}$ ]PIP $_2$  hydrolysis activities of the purified NusA-6His-PLC fusion proteins (20 pmol),  $n = 3 \pm \text{SEM}$ , determined using two different preparations of recombinant protein and with each experiment performed in duplicate. In control experiments with NusA, there was no specific PIP $_2$  hydrolysis activity observed (data not shown). (B) Effect of varying  $[\text{Ca}^{2+}]$  on the normalized activity of NusA-6His-tagged, human and mouse PLC $\zeta$  and human/mouse PLC $\zeta$  chimeric fusion proteins. For these assays  $n = 3 \pm \text{SEM}$ , determined using two different preparations of recombinant protein and with each experiment performed in duplicate.

**Table II** *In vitro* enzymatic properties of NusA-6xHis-tagged human PLC $\zeta$ , mouse PLC $\zeta$  and human/mouse PLC $\zeta$  chimeras.

Recombinant PLC protein	PIP $_2$ hydrolytic enzyme activity (nmol/min/mg)	Ca $^{2+}$ -dependence EC $_{50}$ (nM)	K $_m$ ( $\mu\text{M}$ )
hPLC $\zeta$	978 $\pm$ 34	49	75
mPLC $\zeta$	556 $\pm$ 29	43	99
hPLC $\zeta$ /mEF	782 $\pm$ 33	148	475
hPLC $\zeta$ /mC2	970 $\pm$ 42	40	89
hPLC $\zeta$ /mXYlink	10 $\pm$ 4	–	–

Summary of specific enzyme activity, K $_m$ , and EC $_{50}$  values of Ca $^{2+}$ -dependent enzyme activity for PIP $_2$  hydrolysis, determined by non-linear regression analysis (GraphPad Prism 5) for the NusA-6xHis-fusion PLC proteins (see Fig. 3).

fertilization, triggering all the early events of embryo development in many mammalian species (Cox et al., 2002; Saunders et al., 2002; Nomikos et al., 2012; Swann and Lai, 2013). No other sperm-specific molecule has been shown to trigger  $\text{Ca}^{2+}$  oscillations in mammalian oocytes. Despite recent advances in the PLC $\zeta$  field, which has helped us to understand the role of this sperm-derived enzyme at fertilization and its clinical potential, as a therapeutic intervention and a prognostic

**Table III** Description of parameters used in Equations (1–4) of the mathematical model and their numerical values.


Parameter	Description	Units
A	Ca <sup>2+</sup> influx through non-specific cation channels	0.035 $\mu\text{M}/\text{s}$
D	Rate constant for Ca <sup>2+</sup> extrusion by the ATPase pump	0.64 $\mu\text{M}^{(1-q)}/\text{s}$
q	Exponent for x dependence of Ca <sup>2+</sup> extrusion	2
$x_d$	Half-point of Ca <sup>2+</sup> extrusion ATPase activation sigmoidal	1 $\mu\text{M}$
B	ER uptake rate constant	17.8 $\mu\text{M}/\text{s}$
$x_b$	Half-point of the ER ATPase activation sigmoidal	4.4 $\mu\text{M}$
n	Hill coefficient for x dependence of ER uptake	4
C	InsP <sub>3</sub> -mediated release from InsP <sub>3</sub> -sensitive stores (IICR)	278 $\mu\text{M}/\text{s}$
$y_c$	Half-point of the IICR Ca <sup>2+</sup> efflux sigmoidal	8.9 $\mu\text{M}$
m	Hill coefficient for y dependence of IICR	2
$x_{ca}$	Half-point of the IICR Ca <sup>2+</sup> activation sigmoidal	0.9 $\mu\text{M}$
$p_a$	Hill coefficient for Ca <sup>2+</sup> activation of IICR	2
$x_{ci}$	Half-point of the IICR Ca <sup>2+</sup> inactivation sigmoidal	1.2 $\mu\text{M}$
$p_i$	Hill coefficient for Ca <sup>2+</sup> inactivation of IICR	5
$p_c$	Half-point of the IICR InsP <sub>3</sub> activation sigmoidal	0.1 $\mu\text{M}$
k	Hill coefficient for InsP <sub>3</sub> activation of IICR	2
L	Leak from SR rate constant	0.001/s
PLC $\zeta$ -h	$V_{\text{max}}$ of human PLC $\zeta$	0.035 $\mu\text{M}/\text{s}$
PLC $\zeta$ -m	$V_{\text{max}}$ of mouse PLC $\zeta$	0.018 $\mu\text{M}/\text{s}$
PIP <sub>2</sub>	Concentration of PIP <sub>2</sub>	1.5 $\mu\text{M}$
$K_{m-h}$	Michaelis–Menten constant for human PLC $\zeta$	0.099 $\mu\text{M}$
$K_{m-m}$	Michaelis–Menten constant for mouse PLC $\zeta$	0.075 $\mu\text{M}$
j	Hill coefficient for PLC activation of PIP <sub>2</sub> hydrolysis	1
$x_p$	Half-point of the Ca <sup>2+</sup> activation sigmoidal of InsP <sub>3</sub> production	0.05 $\mu\text{M}$
i	Hill coefficient for Ca <sup>2+</sup> activation of InsP <sub>3</sub> production	4
r	Rate of InsP <sub>3</sub> decay	0.44/s

Specific values for parameter A is presented in the legend of Fig. 4A. Note the different values of PLC $\zeta$  and  $K_m$  for humans and mouse used in numerical simulations presented in Fig. 4A.

indicator of oocyte activation deficiency, there are still many aspects of PLC $\zeta$  regulatory mechanisms that need to be addressed.

There are significant species-specific differences in the relative potency of PLC $\zeta$  from different species (Swann *et al.*, 2006; Saunders *et al.*, 2007; Cooney *et al.*, 2010; Bedford-Guauas *et al.*, 2011). In the present study, we have compared quantitatively and qualitatively the relative potencies of human and mouse PLC $\zeta$  to induce Ca<sup>2+</sup> oscillations in unfertilized mouse oocytes (Fig. 2). Human PLC $\zeta$  caused a higher frequency of Ca<sup>2+</sup> oscillations even when expressed at much lower levels than mouse PLC $\zeta$ . This quantitatively confirms that human PLC $\zeta$  is more effective in generating Ca<sup>2+</sup> oscillations in mouse oocytes than the mouse PLC $\zeta$ . This remarkable difference can largely be explained by the differences in the *in vitro* enzymatic properties of these proteins (Fig. 3) to hydrolyse PIP<sub>2</sub>. In our *in vitro* studies, the purified human PLC $\zeta$  exhibited a  $\sim 76\%$  higher specific activity than mouse PLC $\zeta$  ( $978 \pm 34$  versus  $556 \pm 29$  nmol/min/mg), however, the comparable values for EC<sub>50</sub> and  $K_m$  (see Fig. 4 and Table II) suggest a similar Ca<sup>2+</sup> sensitivity and affinity for PIP<sub>2</sub> for these two PLC $\zeta$  isozymes. This is consistent with a mathematical model of Ca<sup>2+</sup> oscillations (Fig. 5) incorporating the different enzymatic properties of human and mouse PLC $\zeta$  which generates a similar difference in the frequency of Ca<sup>2+</sup> oscillations to that we observe empirically in mouse oocytes.

Our chimeric analysis approach showed that replacement of the human PLC $\zeta$  C2 domain with its mouse counterpart had minimal effect on the *in vitro* enzymatic properties of human PLC $\zeta$  and consequently its potency to elicit Ca<sup>2+</sup> oscillations in unfertilized mouse oocytes. In contrast, replacement of the human PLC $\zeta$  EF-hand domain with that of mouse PLC $\zeta$  resulted in a slightly reduced enzymatic activity, but caused a  $\sim 3$ -fold decrease in the Ca<sup>2+</sup> sensitivity of human PLC $\zeta$ , as well as a  $\sim 6$ -fold increase in the  $K_m$  value for PIP<sub>2</sub>, suggesting reduced substrate affinity of the enzyme. These results correlate with the reduced Ca<sup>2+</sup> oscillation-inducing activity of the hPLC $\zeta$ /mEF chimera and suggest that the EF-hand domains are not only responsible for the Ca<sup>2+</sup> sensitivity of PLC $\zeta$  but might also contribute to the enzyme substrate affinity. The most dramatic effect was observed after the replacement of the human XY-linker with the corresponding region of mouse PLC $\zeta$ . This substitution led to poor expression levels of hPLC $\zeta$ /mXYlink possibly due to significant degradation of unstable recombinant protein (Fig. 3), which would be consistent with the low expression levels of this chimera in mouse oocytes (see Fig. 2, Table I). We have previously proposed that an unstructured positively charged cluster within the XY-linker region of PLC $\zeta$  may help anchor the protein to biological membranes through electrostatic interactions with the negatively charged PIP<sub>2</sub> (Nomikos *et al.*, 2007; 2011c). Interestingly, the amino acid sequence of



**Figure 5** (A)  $\text{Ca}^{2+}$  oscillations in a mouse oocyte were simulated using a mathematical model (Equations 1–3, Appendix) based upon the enzymatic properties of human PLC $\zeta$  (top panel) and mouse PLC $\zeta$  (middle panel). Simulations were performed under a sigmoidal increase of PLC $\zeta$  expression (bottom panel). (B) Clustal alignment of human and mouse sperm PLC $\zeta$  XY-linkers. Identical amino acids are shown in shaded yellow boxes and conservative substitutions in grey.

the XY-linker region of PLC $\zeta$  is poorly conserved among species (Saunders *et al.*, 2007). Notably, the XY-linker of human PLC $\zeta$  is shorter in length and more positively charged than the mouse PLC $\zeta$  XY-linker, showing only 34.2% sequence identity and 18% similarity (see Fig. 5B). The significance of this XY-linker diversity is still unclear, but our data suggest that this variation may contribute to the different rates of PIP $_2$  hydrolysis and relative potency in inducing  $\text{Ca}^{2+}$  oscillations for these two species' PLC $\zeta$  isoform.

The full explanation of why human PLC $\zeta$  is more active than the mouse requires further investigation. However, we can speculate as to why the human sperm may contain a more intrinsically active enzyme. Human and mouse sperm are different in shape but not greatly different in size, and although the amount of PLC $\zeta$  has not been quantified in human sperm it may be similar to that of mouse sperm (Saunders *et al.*, 2002). If this is the case, then the human sperm faces a greater challenge in activating the oocyte. The sperm-derived PLC $\zeta$  is assumed to distribute evenly into the oocyte cytoplasm after gamete fusion. However, the volume of the human oocyte is about five times larger than that of the mouse oocyte, so human PLC $\zeta$  may have to trigger oscillations at much lower concentrations. The current study suggests that this problem may be overcome by human PLC $\zeta$  having at least a 5-fold greater ability to trigger  $\text{Ca}^{2+}$  oscillations. Such species-dependent variation in PLC $\zeta$  potency may enable a precise tuning of the effective 'dose' of PLC $\zeta$  delivered by the sperm, which is adjusted to match the size of the recipient oocyte.

## Acknowledgement

We thank Junaid Kashir for helpful comments on the manuscript.

## Authors' roles

M.N., G.N., K.S. and F.A.L. devised the project strategy, D.P. prepared the mathematical model, M.N. and F.A.L. designed the experiments, which were performed by M.N., K.E., M.T., B.L.C. and L.B., M.N., K.S. and F.A.L. prepared the manuscript.

## Funding

This work was supported by a Wellcome Trust grant 080701. K.E. and M.T. hold research scholarships supported by the Libyan Government and NCSR Demokritos, respectively.

## Conflict of interest

All authors declare that no conflict of interest exists.



## References

- Bedford-Guaus SJ, McPartlin LA, Xie J, Westmiller SL, Buffone MG, Roberson MS. Molecular cloning and characterization of phospholipase C zeta in equine sperm and testis reveals species-specific differences in expression of catalytically active protein. *Biol Reprod* 2011;**85**:78–88.
- Cooney MA, Malcuit C, Cheon B, Holland MK, Fissore RA, D'Cruz NT. Species-specific differences in the activity and nuclear localization of murine and bovine phospholipase C zeta I. *Biol Reprod* 2010;**83**:92–101.
- Cox LJ, Larman MG, Saunders CM, Hashimoto K, Swann K, Lai FA. Sperm phospholipase Czeta from humans and cynomolgus monkeys triggers Ca<sup>2+</sup> oscillations, activation and development of mouse oocytes. *Reproduction* 2002;**124**:611–623.
- Heytens E, Parrington J, Coward K, Young C, Lambrecht S, Yoon SY, Fissore RA, Hamer R, Deane CM, Ruas M *et al*. Reduced amounts and abnormal forms of phospholipase C zeta (PLC $\zeta$ ) in spermatozoa from infertile men. *Hum Reprod* 2009;**24**:2417–2428.
- Kashir J, Heindryckx B, Jones C, De Sutter P, Parrington J, Coward K. Oocyte activation, phospholipase C zeta and human infertility. *Hum Reprod Update* 2010;**16**:690–703.
- Kashir J, Jones C, Lee HC, Rietdorf K, Nikiforaki D, Durrans C, Ruas M, Tee ST, Heindryckx B, Galione A *et al*. Loss of activity mutations in phospholipase C zeta (PLC $\zeta$ ) abolishes calcium oscillatory ability of human recombinant protein in mouse oocytes. *Hum Reprod* 2011;**26**:3372–3387.
- Kashir J, Konstantinidis M, Jones C, Lemmon B, Lee HC, Hamer R, Heindryckx B, Deane CM, De Sutter P, Fissore RA *et al*. A maternally inherited autosomal point mutation in human phospholipase C zeta (PLC $\zeta$ ) leads to male infertility. *Hum Reprod* 2012;**27**:222–231.
- Kouchi Z, Fukami K, Shikano T, Oda S, Nakamura Y, Takenawa T, Miyazaki S. Recombinant phospholipase Czeta has high Ca<sup>2+</sup> sensitivity and induces Ca<sup>2+</sup> oscillations in mouse eggs. *J Biol Chem* 2004;**279**:10408–10412.
- Miyazaki S, Yuzaki M, Nakada K, Shirakawa H, Nakanishi S, Nakade S, Mikoshiba K. Block of Ca<sup>2+</sup> wave and Ca<sup>2+</sup> oscillation by antibody to the inositol 1,4,5-trisphosphate receptor in fertilized hamster eggs. *Science* 1992;**257**:251–255.
- Miyazaki S, Shirakawa H, Nakada K, Honda Y. Essential role of the inositol 1,4,5-trisphosphate receptor/Ca<sup>2+</sup> release channel in Ca<sup>2+</sup> waves and Ca<sup>2+</sup> oscillations at fertilization of mammalian eggs. *Dev Biol* 1993;**158**:62–78.
- Nakano Y, Shirakawa H, Mitsushashi N, Kuwabara Y, Miyazaki S. Spatiotemporal dynamics of intracellular calcium in the mouse egg injected with a spermatozoon. *Mol Hum Reprod* 1997;**3**:1087–1093.
- Nomikos M, Blayney LM, Larman MG, Campbell K, Rossbach A, Saunders CM, Swann K, Lai FA. Role of phospholipase C-zeta domains in Ca<sup>2+</sup>-dependent phosphatidylinositol 4,5-bisphosphate hydrolysis and cytoplasmic Ca<sup>2+</sup> oscillations. *J Biol Chem* 2005;**280**:31011–31018.
- Nomikos M, Mulgrew-Nesbitt A, Pallavi P, Mihalyne G, Zaitseva I, Swann K, Lai FA, Murray D, McLaughlin S. Binding of phosphoinositide-specific phospholipase C-zeta (PLC-zeta) to phospholipid membranes: potential role of an unstructured cluster of basic residues. *J Biol Chem* 2007;**282**:16644–16653.
- Nomikos M, Elgmati K, Theodoridou M, Calver BL, Cumbes B, Nounesis G, Swann K, Lai FA. Male infertility-linked point mutation disrupts the Ca<sup>2+</sup> oscillation-inducing and PIP<sub>2</sub> hydrolysis activity of sperm PLCzeta. *Biochem J* 2011a;**434**:211–217.
- Nomikos M, Elgmati K, Theodoridou M, Georgilis A, Gonzalez-Garcia JR, Nounesis G, Swann K, Lai FA. Novel regulation of PLC $\zeta$  activity via its XY-linker. *Biochem J* 2011b;**438**:427–432.
- Nomikos M, Elgmati K, Theodoridou M, Calver BL, Nounesis G, Swann K, Lai FA. Phospholipase Czeta binding to PtdIns(4,5)P<sub>2</sub> requires the XY-linker region. *J Cell Sci* 2011c;**124**:2582–2590.
- Nomikos M, Swann K, Lai FA. Starting a new life: sperm PLC-zeta mobilizes the Ca<sup>2+</sup> signal that induces egg activation and embryo development: an essential phospholipase C with implications for male infertility. *Bioessays* 2012;**34**:126–134.
- Nomikos M, Yu Y, Elgmati K, Theodoridou M, Campbell K, Vassilakopoulou V, Zikos C, Livanou E, Amso N, Nounesis G *et al*. Phospholipase C $\zeta$  rescues failed oocyte activation in a prototype of male factor infertility. *Fertil Steril* 2013;**99**:76–85.
- Parthimos D, Haddock RE, Hill CE, Griffith TM. Dynamics of a three-variable nonlinear model of vasomotion: comparison of theory and experiment. *Biophys J* 2007;**93**:1534–1556.
- Parthimos D, Edwards DH, Griffith TM. Minimal model of arterial chaos generated by coupled intracellular and membrane Ca<sup>2+</sup> oscillators. *Am J Physiol* 2009;**277**:H1119–H1144.
- Saunders CM, Larman MG, Parrington J, Cox LJ, Royse J, Blayney LM, Swann K, Lai FA. PLC zeta: a sperm-specific trigger of Ca<sup>2+</sup> oscillations in eggs and embryo development. *Development* 2002;**129**:3533–3544.
- Saunders CM, Swann K, Lai FA. PLCzeta, a sperm-specific PLC and its potential role in fertilization. *Biochem Soc Symp* 2007;**74**:23–36.
- Swann K, Lai FA. PLC $\zeta$  and the initiation of Ca<sup>2+</sup> oscillations in fertilizing mammalian eggs. *Cell Calcium* 2013;**53**:55–62.
- Swann K, Saunders CM, Rogers NT, Lai FA. PLC $\zeta$  (zeta): a sperm protein that triggers Ca<sup>2+</sup> oscillations and egg activation in mammals. *Semin Cell Dev Biol* 2006;**17**:264–273.
- Swann K, Campbell K, Yu Y, Saunders C, Lai FA. Use of luciferase chimera to monitor PLCzeta expression in mouse eggs. *Methods Mol Biol* 2009;**518**:17–29.
- Tesarik J, Sousa M, Testart J. Human oocyte activation after intracytoplasmic sperm injection. *Hum Reprod* 1994;**9**:511–518.
- Theodoridou M, Nomikos M, Parthimos D, Gonzalez-Garcia JR, Elgmati K, Calver BL, Sideratou Z, Nounesis G, Swann K, Lai FA. Chimeras of sperm PLC $\zeta$  reveal disparate protein domain functions in the generation of intracellular Ca<sup>2+</sup> oscillations in mammalian eggs at fertilization. *Mol Hum Reprod* 2013;**19**:852–864.
- Vanden Meerschaut F, Leybaert L, Nikiforaki D, Qian C, Heindryckx B, De Sutter P. Diagnostic and prognostic value of calcium oscillatory pattern analysis for patients with ICSI fertilization failure. *Hum Reprod* 2013;**28**:87–98.
- Yazawa H, Yanagida K, Hayashi S, Sato A. The oocyte activation and Ca<sup>2+</sup> oscillation-inducing abilities of mouse and human dead (sonicated) spermatozoa. *Zygote* 2009;**17**:175–184.
- Yoon SY, Jellerette T, Salicioni AM, Lee HC, Yoo MS, Coward K, Parrington J, Grow D, Cibelli JB, Visconti PE *et al*. Human sperm devoid of PLC zeta I fail to induce Ca<sup>2+</sup> release and are unable to initiate the first step of embryo development. *J Clin Invest* 2008;**118**:3671–3681.
- Yoon SY, Eum JH, Lee JE, Lee HC, Kim YS, Han JE, Won HJ, Park SH, Shim SH, Lee WS *et al*. Recombinant human phospholipase C zeta I induces intracellular calcium oscillations and oocyte activation in mouse and human oocytes. *Hum Reprod* 2012;**27**:1768–1780.

## Appendix

The system of coupled differential equations employs cytosolic-free [Ca<sup>2+</sup>], [Ca<sup>2+</sup>] in the ER and [InsP<sub>3</sub>] in the cytosol as independent parameters. Individual ionic fluxes and chemical reactions contributing to these variables are described below.

## Cytosolic-free $\text{Ca}^{2+}$

$$\begin{aligned} \frac{dx}{dt} = & \quad A \quad - \quad Dx^q \quad - \\ & \text{Ca}^{2+} \text{influx} \quad \text{Ca}^{2+} \text{extrusion} \\ & \text{via NSCC} \\ & - \quad B \frac{x^n}{x^n + x_b^n} \quad + \quad C \frac{y^m}{y^m + y_c^m} \frac{x^{p_a}}{x^{p_a} + x_c^{p_a}} \left( 1 - \frac{x^{p_i}}{x^{p_i} + x_c^{p_i}} \right) \frac{p^k}{p^k + p_c^k} \quad + \quad Ly \\ & \text{ER uptake} \quad \text{Ca}^{2+} / \text{InsP}_3 \text{- induced Ca}^{2+} \text{release} \quad \text{Leak from ER} \end{aligned} \quad (1)$$

## $[\text{Ca}^{2+}]$ in the sarcoplasmic reticulum

$$\begin{aligned} \frac{dy}{dt} = & \quad B \frac{x^n}{x^n + x_b^n} \quad - \quad C \frac{y^m}{y^m + y_c^m} \frac{x^{p_a}}{x^{p_a} + x_c^{p_a}} \left( 1 - \frac{x^{p_i}}{x^{p_i} + x_c^{p_i}} \right) \frac{p^k}{p^k + p_c^k} \quad - \quad Ly \\ & \text{ER uptake} \quad \text{Ca}^{2+} / \text{InsP}_3 \text{- induced Ca}^{2+} \text{release} \quad \text{Leak from ER} \end{aligned} \quad (2)$$

## $[\text{InsP}_3]$ in the cytosol

$$\begin{aligned} \frac{dp}{dt} = & \quad \text{PLC}\zeta \frac{\text{PIP}_2^j}{\text{PIP}_2^j + K_m^j} \frac{x^i}{x^i + x_p^i} \quad - \quad rp \\ & \text{InsP}_3 \text{ production by PLC}\zeta \quad \text{InsP}_3 \text{ decay} \end{aligned} \quad (3)$$

All parameters and coefficients used in Equations (1–4) are described in [Table III](#).